Specialty Pharmacy

Three weeks of radiation post-mastectomy observed to be safe and effective for breast cancer patients.

The approach only targets metastatic tissue, reducing negative adverse events associated with chemotherapy.

Top news of the day from across the health care landscape.

HEV is reemerging as a zoonotic virus, with individuals becoming infected via pigs and pork products.

Bacterium may hold the key to preventing resistance to chemotherapy.

Imbruvica is the first FDA-approved therapy to treat cGVHD.

Scientists say ring containing pre-exposure prophylaxis and Truvada is safe in US teens, now need data in African adolescent girls.

The label has been updated to include data from adults co-infected with hepatitis C virus and HIV-1.

Jon Gavras, MD, chief medical officer at Prime Therapeutics, explores how combining medical and pharmacy benefits could result in a better understanding of a certain drug's value.

The first of a 2-part series on the influential women shaping the specialty pharmacy industry.

Nivolumab approved for form of metastatic colorectal cancer that typically does not respond to chemotherapy.

Enasidenib, an oral inhibitor for relapsed or refractory acute myeloid leukemia, shows promise in achieving a complete response with hematologic improvement.

New treatment strategies for rheumatoid arthritis led to a reduction in congestive heart failure and cardiovascular mortality after the year 2000.

Combining old and new technology may provide superior oncologic outcomes for patients with resectable lung cancer.

Study will compare the pharmacokinetics and clinical outcomes between Humira biosimilar and its reference product in the treatment of moderate-to-severe chronic plaque psoriasis.

Top news of the day from across the health care landscape.

Increased efforts in prevention and treatment for HIV show promise in high-burden regions.

Pharmacists crack the top 5 of most competitive in-demand jobs with 6-figure salaries.

The upcoming National Association of Specialty Pharmacy conference will focus on the evolution of the industry.

PCMA report suggests that DIR fees will save $308.2 billion between 2017 and 2026, while critics say the report is misleading.

Direct and indirect remuneration fees continue to generate controversy across the pharmacy landscape.

Discovery may lead to new immunotherapies for aggressive breast cancer.

Top news of the day from across the health care landscape.

More than half of survey respondents with HIV reported concerns about possible drug-drug interactions.

Long-acting HIV medications could solve problems with adherence, reduce costly laboratory tests to monitor their efficacy, and bring down drug costs.

Technique offers improved survival in patients with advanced, inoperable stage 3 non-small cell lung cancer.

Top articles of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.